Literature DB >> 27782467

A fast, open source implementation of adaptive biasing potentials uncovers a ligand design strategy for the chromatin regulator BRD4.

Bradley M Dickson1, Parker W de Waal2, Zachary H Ramjan1, H Eric Xu2, Scott B Rothbart1.   

Abstract

In this communication we introduce an efficient implementation of adaptive biasing that greatly improves the speed of free energy computation in molecular dynamics simulations. We investigated the use of accelerated simulations to inform on compound design using a recently reported and clinically relevant inhibitor of the chromatin regulator BRD4 (bromodomain-containing protein 4). Benchmarking on our local compute cluster, our implementation achieves up to 2.5 times more force calls per day than plumed2. Results of five 1 μs-long simulations are presented, which reveal a conformational switch in the BRD4 inhibitor between a binding competent and incompetent state. Stabilization of the switch led to a -3 kcal/mol improvement of absolute binding free energy. These studies suggest an unexplored ligand design principle and offer new actionable hypotheses for medicinal chemistry efforts against this druggable epigenetic target class.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27782467      PMCID: PMC5074994          DOI: 10.1063/1.4964776

Source DB:  PubMed          Journal:  J Chem Phys        ISSN: 0021-9606            Impact factor:   3.488


  23 in total

1.  Fluorescence polarization competition assay: the range of resolvable inhibitor potency is limited by the affinity of the fluorescent ligand.

Authors:  Xinyi Huang
Journal:  J Biomol Screen       Date:  2003-02

2.  Approaching a parameter-free metadynamics.

Authors:  Bradley M Dickson
Journal:  Phys Rev E Stat Nonlin Soft Matter Phys       Date:  2011-09-19

3.  First drugs found to inhibit elusive cancer target.

Authors:  Melinda Wenner Moyer
Journal:  Nat Med       Date:  2011-11-07       Impact factor: 53.440

4.  μ-tempered metadynamics: Artifact independent convergence times for wide hills.

Authors:  Bradley M Dickson
Journal:  J Chem Phys       Date:  2015-12-21       Impact factor: 3.488

5.  Routine Microsecond Molecular Dynamics Simulations with AMBER on GPUs. 2. Explicit Solvent Particle Mesh Ewald.

Authors:  Romelia Salomon-Ferrer; Andreas W Götz; Duncan Poole; Scott Le Grand; Ross C Walker
Journal:  J Chem Theory Comput       Date:  2013-08-20       Impact factor: 6.006

6.  Well-tempered metadynamics: a smoothly converging and tunable free-energy method.

Authors:  Alessandro Barducci; Giovanni Bussi; Michele Parrinello
Journal:  Phys Rev Lett       Date:  2008-01-18       Impact factor: 9.161

7.  A boundary correction algorithm for metadynamics in multiple dimensions.

Authors:  Michael McGovern; Juan de Pablo
Journal:  J Chem Phys       Date:  2013-08-28       Impact factor: 3.488

8.  SwissParam: a fast force field generation tool for small organic molecules.

Authors:  Vincent Zoete; Michel A Cuendet; Aurélien Grosdidier; Olivier Michielin
Journal:  J Comput Chem       Date:  2011-05-03       Impact factor: 3.376

Review 9.  Inhibition of bromodomain and extra-terminal proteins (BET) as a potential therapeutic approach in haematological malignancies: emerging preclinical and clinical evidence.

Authors:  Aristeidis Chaidos; Valentina Caputo; Anastasios Karadimitris
Journal:  Ther Adv Hematol       Date:  2015-06

10.  The structure-activity relationships of L3MBTL3 inhibitors: flexibility of the dimer interface.

Authors:  Michelle A Camerino; Nan Zhong; Aiping Dong; Bradley M Dickson; Lindsey I James; Brandi M Baughman; Jacqueline L Norris; Dmitri B Kireev; William P Janzen; Cheryl H Arrowsmith; Stephen V Frye
Journal:  Medchemcomm       Date:  2013-11       Impact factor: 3.597

View more
  8 in total

1.  Rolapitant Is a Reversible Inhibitor of CYP2D6.

Authors:  Sarah M Glass; Sabrina M Leddy; Michael C Orwin; Garret P Miller; Kyle A Furge; Laura Lowe Furge
Journal:  Drug Metab Dispos       Date:  2019-04-05       Impact factor: 3.922

2.  Cryo-EM structure of human rhodopsin bound to an inhibitory G protein.

Authors:  Yanyong Kang; Oleg Kuybeda; Parker W de Waal; Somnath Mukherjee; Ned Van Eps; Przemyslaw Dutka; X Edward Zhou; Alberto Bartesaghi; Satchal Erramilli; Takefumi Morizumi; Xin Gu; Yanting Yin; Ping Liu; Yi Jiang; Xing Meng; Gongpu Zhao; Karsten Melcher; Oliver P Ernst; Anthony A Kossiakoff; Sriram Subramaniam; H Eric Xu
Journal:  Nature       Date:  2018-06-13       Impact factor: 49.962

3.  Tryptophan-75 Is a Low-Energy Channel-Gating Residue that Facilitates Substrate Egress/Access in Cytochrome P450 2D6.

Authors:  Kevin D McCarty; Samuel A Ratliff; Kyle A Furge; Laura Lowe Furge
Journal:  Drug Metab Dispos       Date:  2020-12-29       Impact factor: 3.922

4.  Modern drug design: the implication of using artificial neuronal networks and multiple molecular dynamic simulations.

Authors:  Oleksandr Yakovenko; Steven J M Jones
Journal:  J Comput Aided Mol Des       Date:  2017-11-13       Impact factor: 3.686

5.  Molecular mechanisms of fentanyl mediated β-arrestin biased signaling.

Authors:  Parker W de Waal; Jingjing Shi; Erli You; Xiaoxi Wang; Karsten Melcher; Yi Jiang; H Eric Xu; Bradley M Dickson
Journal:  PLoS Comput Biol       Date:  2020-04-10       Impact factor: 4.475

6.  The finger loop of the SRA domain in the E3 ligase UHRF1 is a regulator of ubiquitin targeting and is required for the maintenance of DNA methylation.

Authors:  Robert M Vaughan; Scott B Rothbart; Bradley M Dickson
Journal:  J Biol Chem       Date:  2019-09-03       Impact factor: 5.157

7.  Attach-Pull-Release Calculations of Ligand Binding and Conformational Changes on the First BRD4 Bromodomain.

Authors:  Germano Heinzelmann; Niel M Henriksen; Michael K Gilson
Journal:  J Chem Theory Comput       Date:  2017-06-13       Impact factor: 6.006

8.  Identification of a Novel Class of BRD4 Inhibitors by Computational Screening and Binding Simulations.

Authors:  Bryce K Allen; Saurabh Mehta; Stuart W J Ember; Jin-Yi Zhu; Ernst Schönbrunn; Nagi G Ayad; Stephan C Schürer
Journal:  ACS Omega       Date:  2017-08-21
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.